SCHEMBL55591

SCHEMBL55591

O=C(O)C1CCCNC1=O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.61
POLB P06746 2/20 0.51
HTT P42858 1/20 0.46
ALDH1A1 P00352 1/20 0.46
KLK5 Q9Y337 1/20 0.44
MEN1 O00255 1/20 0.43
CYP1A2 P05177 1/20 0.43
KMT2A Q03164 1/20 0.43
GAA P10253 3/20 0.42
KDM4E B2RXH2 1/20 0.41
HPGD P15428 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
TSHR P16473 1/20 0.41
HSD17B10 Q99714 1/20 0.41
GLA P06280 1/20 0.40
HDAC3 O15379 2/20 0.40
HDAC1 Q13547 2/20 0.40
HDAC2 Q92769 2/20 0.40
HDAC10 Q969S8 2/20 0.40
HDAC11 Q96DB2 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14812115 1.00 L3MBTL1 (0.61) L3MBTL1POLBHTTALDH1A1KLK5
SCHEMBL14811830 1.00 L3MBTL1 (0.61) L3MBTL1POLBHTTALDH1A1KLK5
SCHEMBL1278442 0.94 L3MBTL1 (0.55) L3MBTL1POLBHTTALDH1A1KLK5
SCHEMBL1290904 0.94 L3MBTL1 (0.55) L3MBTL1POLBHTTALDH1A1KLK5
SCHEMBL24108598 0.86
SCHEMBL149411 0.86
SCHEMBL28051654 0.86
SCHEMBL940890 0.82 L3MBTL1 (0.45) L3MBTL1POLBHTTALDH1A1MEN1
SCHEMBL30693669 0.81 L3MBTL1 (0.59) L3MBTL1POLBHTTALDH1A1KLK5
SCHEMBL27774970 0.81 L3MBTL1 (0.59) L3MBTL1POLBHTTALDH1A1KLK5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023158722-A2 PROCESSES FOR PREPARATION OF AVACOPAN AND INTERMEDIATES THEREOF TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) 2023-08-24 WO claimed
CN-103732577-B As effective hdac inhibitor carrying lactams thio derivative and they as medicine purposes 希格马托制药工业公司 2017-04-05 CN claimed
EP-2758371-B1 NEW THIO DERIVATIVES BEARING LACTAMS AS POTENT HDAC INHIBITORS AND THEIR USES AS MEDICAMENTS SIGMA TAU IND FARMACEUTI (IT) 2016-06-15 EP claimed
US-8927533-B2 Thio derivatives bearing lactams as potent HDAC inhibitors and their uses as medicaments SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) 2015-01-06 US claimed
EP-2758371-A1 NEW THIO DERIVATIVES BEARING LACTAMS AS POTENT HDAC INHIBITORS AND THEIR USES AS MEDICAMENTS SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) 2014-07-30 EP claimed
WO-2013041480-A1 NEW THIO DERIVATIVES BEARING LACTAMS AS POTENT HDAC INHIBITORS AND THEIR USES AS MEDICAMENTS SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) 2013-03-28 WO claimed
EP-2029235-A1 METHOD FOR STRAIGHTENING KERATINOUS FIBERS USING HEATING MEANS AND AN AMIDE L'Oréal (FR) 2009-03-04 EP claimed
WO-2007135296-A1 METHOD FOR STRAIGHTENING KERATINOUS FIBERS USING HEATING MEANS AND AN AMIDE L'OREAL (FR) 2007-11-29 WO claimed
EP-4294804-B1 PYRIDONE COMPOUNDS AND METHODS OF USE EXELIXIS INC (US) 2026-04-08 EP disclosed
EP-4680375-A1 SYSTEM AND METHOD FOR FLUID CAPTURE GE Vernova Technology GmbH (CH) 2026-01-21 EP disclosed
EP-4680252-A1 SYSTEM AND METHOD FOR FLUID CAPTURE GE Vernova Infrastructure Technology LLC (US) 2026-01-21 EP disclosed
US-20250346602-A1 LACTAM SUBSTITUTED IMIDAZOPYRIDAZINE IL-17A MODULATORS AND USES THEREOF DICE ALPHA INC (US) 2025-11-13 US disclosed
EP-4629980-A1 ANTIMICROBIAL COMPOUNDS SRI International (US) 2025-10-15 EP disclosed
US-12421232-B2 Kinase inhibitor compounds and compositions and methods of use ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2025-09-23 US disclosed
US-5504101-A TRYPTAMINE ANALOGS ALLELIX BIOPHARMACEUTICALS, INC. (CA) 1996-04-02 US disclosed
US-5496957-A 5-HYDOXYTRYPTAMINE VIRGINIA COMMONWEALTH UNIVERSITY (US) 1996-03-05 US disclosed
WO-1995030655-A1 TRYPTAMINE DERIVATIVES AS 5-HT-1D RECEPTOR LIGANDS ALLELIX BIOPHARMACEUTICALS INC. (CA) 1995-11-16 WO disclosed
EP-0666847-A1 TRYPTAMINE ANALOGS WITH 5-HT1D SELECTIVITY Allelix Biopharmaceuticals Inc. (CA) 1995-08-16 EP disclosed
WO-1995006638-A1 TRYPTAMINE ANALOGS WITH 5-HT1D SELECTIVITY ALLELIX BIOPHARMACEUTICALS INC. (CA) 1995-03-09 WO disclosed
US-4252803-A HYPOTENSIVE AGENTS, ANALGESICS GLAXO GROUP LIMITED (GB) 1981-02-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250346602-A1 LACTAM SUBSTITUTED IMIDAZOPYRIDAZINE IL-17A MODULATORS AND USES THEREOF IL17A, IL15, IL18 L3MBTL1 4848/4885POLB 2245/4885HTT 4861/4885
US-12421232-B2 Kinase inhibitor compounds and compositions and methods of use CSNK1A1, DYRK1A, CSNK1G3 L3MBTL1 3307/4885POLB 1513/4885HTT 1554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.